DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cystic Fibrosis Related Diabetes (CFRD) is present in approximately 40% of adult patients with cystic fibrosis and is associated with increased morbidity and mortality. Patients with CFRD are not routinely treated with exogenous insulin when their fasting glucose levels are normal. We hypothesize that chronic treatment with either insulin or an oral stimulator of endogenous insulin will lead to improved muscle mass and clinical status in adult CF patients with CFRD without fasting hyperglycemia. This is a multi-center, prospective, placebo-controlled intervention trial coordinated by Antoinette Moran, M.D. at the University of Minnesota. Subjects will be treated for 12 months with either insulin or repaglinide or an oral placebo. The effects of these agents on muscle mass, body weight, body composition and pulmonary function will be evaluated.